At 10am on March 28, 2023, a meeting was held in the lecture hall of the College of Chemical Engineering of Northwest Normal University for the 2023 spring campus recruitment of professionals. Wang Youwei, general manager of Kangyuxin Biology and other department heads, teachers from Northwest Normal College of Chemical Engineering and more than 50 graduates participated in the meeting.
At 9:30 am, the leaders of both sides of Kangyuxin College of Biology and Chemical Engineering exchanged views on matters related to the meeting and reached a consensus. At the beginning of the meeting, the general manager of Kangyuxin made a detailed description to the participants in the form of PPT on the direction of our company's professional engagement, development history, company output value, industry status, cooperation customers and other aspects. Next is Wu Chao, head of the company's research and development team, who is also a senior graduate of Northwest Normal University in 2016, gave a detailed introduction to the company's research and development work, and finally the company's human resources director explained in detail the job needs, salary, welfare and insurance, and personal promotion space.
Before the end of the lecture, the person in charge of the company gave a brief question-and-answer session to the students. The students asked questions about career development, promotion path, salary and so on. The person in charge gave detailed answers and suggestions to each student who asked questions. At this point, the Kangyuxin Biological 2022 Spring Festival campus recruitment came to a successful end.
Kang Yu Xin biological
Kangyuxin Biotechnology Co., Ltd. was established in October 2013, specializing in the research and development, production, sales and related service technology development of pyrazine intermediates and process libraries. Kangyuxin has more than 2,000 square meters of standardized laboratories, with an output value of more than 80 million yuan in 2022. The core technology of pyrazine derivatives of Kangyuxin ranks the leading level in China, and the varieties and orders of pyrazine series products are ranked first in the domestic industry. Kangyuxin has an experienced and high-quality drug process research and development team, which can realize the research and development and process production from lead compounds to clinical batch apis. Kangyuxin Drug Quality research team can provide effective data and method validation for drug registration and research.
The company was supported by the innovation Fund of Gansu Province in 2016, and was identified as the first batch of provincial science and technology innovation enterprises by the Department of Science and Technology of Gansu Province, and has been supported by the science and technology innovation Fund of Lanzhou and Baiyin for many times. Wang Youwei, the founder of the company, was named "One hundred innovative and entrepreneurial models in Lanzhou City" in 2015. Kangyuxin, as the first enterprise to develop a broad spectrum antiviral new drug "Fabilavir" in China, was shortlisted in the list of the eighth batch of key protection enterprises for epidemic prevention materials in Gansu Province, Kangyuxin won the excellence Award of the 10th China Innovation and Entrepreneurship Competition National Biomedical Industry Competition in 2021 (the second place in the group), and the second place in the Gansu Division of the 10th China Innovation and Entrepreneurship Competition. Won the first prize in the Northwest region of the 2020 "Guotong Cup" Lanzhou University Global Alumni Entrepreneurship Competition, and the first prize of the Baiyin Double Innovation Competition for two consecutive years in 2020 and 2021. In 2022, it will be evaluated as a high-tech enterprise and a specialized and special new enterprise.
